Archive · 3 Oct 2025
Trump Administration Reviews Medicare Drug Pricing Pilot
The Trump administration is considering a new plan to potentially lower drug prices for older adults.
This plan involves a pilot project, like a test run, to see if new rules can save money.
The government's health insurance program for seniors, Medicare, buys a lot of medicine, so this could have a big effect.
The goal is to try out these rules before making them official.
This comes after an earlier move toward similar regulations.
Pharmaceutical companies have expressed opposition.
The stock market is watching closely, as new rules could affect how much these companies make.
A deal with Pfizer highlights the potential for companies to negotiate with the government.
A CMS pilot project on Medicare drug pricing is under review.
The project's details, including impacted drugs and companies, are not specified.
Regulatory pilot projects test the effectiveness of new rules before wider implementation.
This initiative follows a previous move towards new drug price regulations.
The pharmaceutical industry has historically opposed such measures.
- Who
- The Trump administration and CMS
- What
- Are reviewing a new regulatory pilot project related to Medicare drug pricing
- When
- The pilot project is under review at the White House budget office
- Where
- United States
- Why
- To potentially lower what Medicare pays for drug prices.
- Agency
- US Centers for Medicare and Medicaid Services (CMS)
- Project Title
- Guarding US Medicare Against Rising Drug Costs
- Focus
- Medicare drug prices
- Objective
- Determine if new regulation will save money
- Action
- Regulatory pilot project under review
- Context
- Second recent move toward new rules on drug prices